Searched for
GRANULES PHARMA SHARE PRICE
Auto ancillary stocks: Time for a re-rating as transformation nears the finish line? 6 stocks with upside potential of up to 34%When auto companies do well, it is an indication that the underlying health of the economy is not bad. The reason why we are using the word...
Two Trades for Today: A top solar PV cell maker for a 7.95% upmove, a mid-cap telecom sector stock for a 7% gainOur technical analysts identify select stocks every trading day that may gain momentum even in volatile markets. Here are the technical cal...
For long-term investors: Boring portfolio that wins difficult years; 5 large-cap stocks with upside potential up to 20%A sector leader is not just the company with the largest market share. Market share matters, but it is a result, not a cause. The cause is ...
Stock picks of the week: 5 stocks with consistent score improvement and upside potential of up to 26%The bulls, who were making a comeback attempt after the US-Iran peace deal, have been hit by the global meltdown in IT services stocks. As ...
Sun Pharma adds Innovcare to its fold in Rs 271.2 crore all-cash transactionIndia's largest drugmaker, Sun Pharma, is set to acquire Mumbai-based Innovcare Lifesciences for approximately $28.7 million in an all-cash...
Rs 40,000 crore gone in minutes! Why Infosys shares crashed 9% to hit lowest level in almost 6 yearsInfosys share price: Infosys shares plummeted 9% to a near 6-year low, losing nearly Rs 40,000 crore in market cap. This follows Accenture'...
Societe General, Prudential, others buy 3 per cent stake in Anthem Biosciences for Rs 1,275 crGlobal investors including Societe Generale and Prudential Hong Kong, alongside Indian mutual funds and insurance companies, have bought a ...
Time for long-term investors to look at them again? 9 NBFC stocks with upside potential of up to 22%The reason NBFC stocks reacted quickly to the easing of the US-Iran war risk is not difficult to understand. For a lender, macro relief tra...
Weekly Top Picks: These stocks scored 10 on 10 on Stock Reports PlusStock Reports Plus, powered by Refinitiv, undertakes detailed company analysis for 4,000+ listed stocks. In addition to detailed company an...
These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analystsFrom a macro perspective, it is clearly a good time to be bullish. But as valuations remain high in parts of the market despite the recent ...
Weekly Top Picks: These stocks scored 10 on 10 on Stock Reports PlusStock Reports Plus, powered by Refinitiv, undertakes detailed company analysis for 4,000+ listed stocks. In addition to detailed company an...
These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of up to 27%As the market seems to be in comeback mode, it helps to be aware that the best (and probably biggest) wealth creator of the last couple of ...
Capitalmind Flexi Cap Fund adds Nestle India and 10 others, exits SBI and 14 others in MayCapitalmind Flexi Cap Fund made significant portfolio adjustments in May. The fund welcomed Nestle India and eleven new stocks. It also div...
Two Trades for Today: A realty major for a 6.6% rise, a mid-cap fertiliser maker’s stock for a 7% gainOur technical analysts identify select stocks every trading day that may gain momentum even in volatile markets. Here are the technical cal...
Zydus Lifesciences shares fall 2% as firm acquires US-based Assertio Holdings for $166 millionZydus Lifesciences' shares dipped 2% after completing the $166.4 million acquisition of US-based Assertio Holdings Inc. The deal, finalized...
Top Nifty50 stocks analysts suggest buying in this volatile weekStock Reports Plus, powered by Refinitiv, is a comprehensive report that evaluates five key components of 4,000+ listed stocks – earnings, ...
Weekly Top Picks: These stocks scored 10 on 10 on Stock Reports PlusStock Reports Plus, powered by Refinitiv, undertakes detailed company analysis for 4,000+ listed stocks. In addition to detailed company an...
Two Trades for Today: 2 pharma companies – a large-cap for a 5% rise, and a mid-cap stock for a gain of 7%Our technical analysts identify select stocks every trading day that may gain momentum even in volatile markets. Here are the technical cal...
Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplashIndian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...
Promoter sells Rs 1,024 crore worth of Ajanta Pharma shares in block deal to Kotak MF and ABSL MFA promoter entity of Ajanta Pharma sold shares worth over Rs 1,024 crore through a block deal, with Kotak Mahindra Mutual Fund and Aditya B...